• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Semler Scientific Inc.

    2/28/25 5:16:51 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SMLR alert in real time by email
    S-8 1 tm257507d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-      

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

    Semler Scientific, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware 26-1367393
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
       

    2340-2348 Walsh Avenue, Suite 2344

    Santa Clara, CA

     

    95051

    (Addresses of Principal Executive Officers) (Zip Code)

     

    (877) 774-4211

    (Registrant’s telephone number, including area code)

     

     

     

    Semler Scientific, Inc. 2024 Stock Option and Incentive Plan

    (Full title of the plan)

     

     

     

    Douglas Murphy-Chutorian, M.D.

    Chief Executive Officer

    Semler Scientific, Inc.

    2340-2348 Walsh Avenue, Suite 2344

    Santa Clara, CA 95051

    (Name and address of agent for service)

     

    (877) 774-4211

    (Telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Marianne Sarrazin, Esq.

    Goodwin Procter LLP

    525 Market 32nd Floor

    San Francisco, California 94105

    Tel: (415) 733-6134

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B)  of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 is being filed by Semler Scientific, Inc. with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 382,259 shares of the registrant’s common stock, par value $0.001 per share, to be issued pursuant to the Semler Scientific, Inc. 2024 Stock Option and Incentive Plan (the “2024 Plan”). This registration statement relates to securities of the same class as other securities for which a registration statement on Form S-8 related to the 2024 Plan has previously been filed and is effective. Accordingly, pursuant to General Instruction E, the information contained in the registrant’s registration statement on Form S-8 (File No. 333-283009) is hereby incorporated by reference and made part of this registration statement.

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The registrant hereby incorporates by reference into this registration statement the following documents filed with the Commission:

     

    (a)The registrant’s annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025;

     

    (b)The registrant’s current reports on Form 8-K filed on January 13, 2025, January 23, 2025 (Item 8.01 only), January 24, 2025, January 28, 2025 and February 4, 2025; and

     

    (c)the description of our common stock contained in our registration statement on Form 8-A filed on September 27, 2021, as the description therein has been updated and superseded by the description of our capital stock contained in Exhibit 4.2 to our annual report on Form 10-K for the fiscal year ended December 31, 2024, and including any amendments and reports filed for the purpose of updating such description.

     

    All reports and other documents that the registrant subsequently files with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this registration statement that indicates that all of the shares of common stock offered have been sold or that deregisters all of such shares then remaining unsold shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K, or any exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
         
    4.1   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on November 2, 2015).  
         
    4.2   Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Semler Scientific, Inc. (incorporated by reference to Exhibit 3.1 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on October 23, 2023).  
         
    4.3   Third Amended and Restated Bylaws of Semler Scientific, Inc. (incorporated by reference to Exhibit 3.1 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on April 19, 2023).  
         
    4.4   Specimen Common Stock certificate (incorporated by reference to Exhibit 4.1 to Amendment No. 1 of the registrant’s Form S-1 (File No. 333-192362) filed with the Securities and Exchange Commission on December 6, 2013).  
         
    5.1*   Opinion of Goodwin Procter LLP.
         
    23.1*   Consent of BDO USA, P.C., independent registered public accounting firm.
         
    23.2*   Consent of Goodwin Procter LLP (included in Exhibit 5.1)
         
    24.1*   Power of Attorney (included on the signature page to this Registration Statement)
         
    99.1   Semler Scientific, Inc. 2024 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed with the Securities and Exchange Commission on October 8, 2024).  
         
    99.2   Form of Incentive Stock Option Agreement under the 2024 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.2 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on October 8, 2024).  
         
    99.3   Form of Non-Qualified Stock Option Agreement for Company Employees and Consultants under the 2024 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.3 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on October 8, 2024).  
         
    99.4   Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under the 2024 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.4 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on October 8, 2024).  
         
    99.5   Form of Restricted Stock Unit Award Agreement for Company Employees and Consultants under the 2024 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.5 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on October 8, 2024).  
         
    99.6   Form of Restricted Stock Unit Award Agreement for Non-Employee Directors under the 2024 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.6 of the registrant’s Form 8-K filed with the Securities and Exchange Commission on October 8, 2024).  
         
    107*   Calculation of Filing Fee Table.

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Santa Clara, State of California, on the 28th day of February, 2025.

     

      Semler Scientific, Inc.
       
      By: /s/ Douglas Murphy-Chutorian
      Name: Douglas Murphy-Chutorian, M.D.
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Douglas Murphy-Chutorian and Renae Cormier, and each of them, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the date indicated below.

     

    Signature Title Date
         
    /s/ Douglas Murphy-Chutorian Director and Chief Executive Officer February 28, 2025
    Douglas Murphy-Chutorian, M.D. (Principal Executive Officer)  
         
    /s/ Renae Cormier Chief Financial Officer February 28, 2025
    Renae Cormier (Principal Financial and Accounting Officer)  
         
    /s/ Eric Semler Chairman of the Board February 28, 2025
    Eric Semler    
         
    /s/ William H.C. Chang Director February 28, 2025
    William H.C. Chang    
         
    /s/ Daniel Messina Director February 28, 2025
    Daniel Messina    

     

     

     

    Get the next $SMLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMLR

    DatePrice TargetRatingAnalyst
    7/28/2025Overweight
    Cantor Fitzgerald
    7/8/2025$101.00Buy
    The Benchmark Company
    11/2/2022$60.00 → $45.00Buy → Neutral
    B. Riley Securities
    3/7/2022$145.00 → $70.00Buy
    B. Riley Securities
    11/2/2021$175.00 → $145.00Buy
    B. Riley Securities
    10/26/2021$151.00 → $175.00Buy
    B. Riley Securities
    More analyst ratings

    $SMLR
    SEC Filings

    View All

    SEC Form 15-12G filed by Semler Scientific Inc.

    15-12G - Semler Scientific, Inc. (0001554859) (Filer)

    1/26/26 4:16:39 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Semler Scientific Inc.

    EFFECT - Semler Scientific, Inc. (0001554859) (Filer)

    1/22/26 12:15:03 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Semler Scientific Inc.

    EFFECT - Semler Scientific, Inc. (0001554859) (Filer)

    1/22/26 12:15:04 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Semler Eric was granted 1,318 shares and bought $1,896,500 worth of shares (50,000 units at $37.93), increasing direct ownership by 9% to 621,721 units (SEC Form 4)

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    11/12/24 6:05:40 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Strive Announces the Completion of Semler Scientific Acquisition

    DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST) ("Strive") today announced the successful completion of the previously announced acquisition of Semler Scientific. Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally. Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy's initial focus will be on Strive's intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.  Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Ba

    1/16/26 8:40:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Strive, Inc. (Nasdaq: ASST) and Semler Scientific (Nasdaq: SMLR) Announce Shareholder Approval for Acquisition of Semler Scientific

    DALLAS, TX and CAMPBELL, CA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. ("Strive") announces Semler Scientific, Inc. ("Semler Scientific") stockholders voted to approve being acquired by Strive. As part of the all-stock transaction, Strive will acquire Semler Scientific's 5,048.1 Bitcoin. Strive also announces the purchase of 123 additional Bitcoin for its corporate treasury at an average price of $91,561 per Bitcoin, for a total purchase price of $11,264,000, inclusive of fees and expenses, bringing Strive's total Bitcoin holdings to 7,749.8. Upon completion of the Semler Scientific acquisition, the combined company will hold 12,797.9 Bitcoin, surpassing both Tesla and Trump Media &

    1/13/26 12:02:00 PM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® to Release Third Quarter 2025 Financial Results

    CAMPBELL, Calif., Oct. 28, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical devices and software to combat chronic diseases, today announced that due to its pending transaction with Strive, Inc., the company will not be hosting a conference call or providing an accompanying earnings presentation in conjunction with its third quarter 2025 financial results. Semler Scientific intends to file its Quarterly Report on Form 10-Q for the period ended September 30,

    10/28/25 5:05:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Semler Eric returned 714,117 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    1/16/26 3:22:32 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CEO, interim CFO and Director Murphy-Chutorian Douglas returned 241,303 shares to the company (SEC Form 4)

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    1/16/26 3:21:35 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Messina Daniel S returned 11,910 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Semler Scientific, Inc. (0001554859) (Issuer)

    1/16/26 3:20:36 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Semler Scientific

    Cantor Fitzgerald initiated coverage of Semler Scientific with a rating of Overweight

    7/28/25 9:00:02 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    The Benchmark Company initiated coverage on Semler Scientific with a new price target

    The Benchmark Company initiated coverage of Semler Scientific with a rating of Buy and set a new price target of $101.00

    7/8/25 8:33:26 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Semler Scientific from Buy to Neutral and set a new price target of $45.00 from $60.00 previously

    11/2/22 6:23:13 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Leadership Updates

    Live Leadership Updates

    View All

    Strive Announces the Completion of Semler Scientific Acquisition

    DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST) ("Strive") today announced the successful completion of the previously announced acquisition of Semler Scientific. Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally. Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy's initial focus will be on Strive's intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.  Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Ba

    1/16/26 8:40:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction

    DALLAS, TX and CAMPBELL, CA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. ("Strive") entered into a definitive agreement to acquire Semler Scientific, Inc. ("Semler Scientific") in an all-stock transaction. In addition, Strive announced the purchase of 5,816 Bitcoin to its corporate treasury at an average price of $116,047 per Bitcoin, for a total purchase price of $675,000,000, inclusive of fees and expenses, bringing Strive's total Bitcoin holdings to 5,886. Transaction details: Deal represents an approximately 210% premium, equivalent to approximately $90.52 per share, based on the trading price of Semler Scientific common stock and Strive Class A common stock as of the market clos

    9/22/25 8:15:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Appoints Joe Burnett as Director of Bitcoin Strategy; Targets Owning at Least 10,000 Bitcoins by Year-End 2025 and 105,000 by Year-End 2027

    CAMPBELL, Calif., June 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Joe Burnett as director of Bitcoin strategy. Semler Scientific also announced that it plans to hold 10,000 Bitcoins by year-end 2025, 42,000 by year-end 2026 and 105,000 by year-end 2027, using proceeds from equity and debt financings and cash flows from operations.  "We are excited to have Joe join our Bitcoin strategy

    6/19/25 4:45:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    11/12/24 4:15:46 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SMLR
    Financials

    Live finance-specific insights

    View All

    Semler Scientific® to Release Third Quarter 2025 Financial Results

    CAMPBELL, Calif., Oct. 28, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical devices and software to combat chronic diseases, today announced that due to its pending transaction with Strive, Inc., the company will not be hosting a conference call or providing an accompanying earnings presentation in conjunction with its third quarter 2025 financial results. Semler Scientific intends to file its Quarterly Report on Form 10-Q for the period ended September 30,

    10/28/25 5:05:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Reports Second Quarter 2025 Financial Results, BTC Holdings of 5,021 and BTC Yield of 31.3% YTD through July 31, 2025

    CAMPBELL, Calif., Aug. 4, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its Bitcoin holdings and other key performance indicators (KPIs). "We have made excellent progress with our Bitcoin treasury strategy," said Eric Semler, executive chairman of Semler Scientific. "We purchased approximately $195.4 million of Bitcoin s

    8/4/25 4:01:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC

    CAMPBELL, Calif., May 13, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its bitcoin holdings and other key performance indicators (KPIs). "We continue to accretively grow our bitcoin arsenal using operating cash flow and proceeds from debt and equity financings," said Eric Semler, chairman of Semler Scientific. "And we a

    5/13/25 4:01:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care